Category: Biotech

Summit Therapeutics plc ( SMMT )

Published: 04 October 2016
Written by Editor
Nasdaq   Up on News   Project Update  

Summit to Host Conference Call to Discuss Exclusive License and Collaboration Agreement With Sarepta Therapeutics for European Rights to Summit’s Utrophin Modulator Pipeline for the Treatment of Duchenne Muscular Dystrophy

OXFORD, United Kingdom, Oct. 04, 2016  -- Summit Therapeutics plc (SMMT) (SUMM.L), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy (‘DMD’) and Clostridium difficileinfection, announces that in conjunction with today’s announcement on an exclusive license and collaboration agreement with Sarepta Therapeutics for European rights to Summit’s utrophin modulator pipeline for the treatment of DMD, Summit will be holding a conference call at 1:00pm BST / 8:00am EDT.
To participate in the conference call, please dial +44(0)20 3427 1918 (UK and international participants) or +1 646 254 3365 (US local number) and use the conference confirmation code 6907795. Investors may also access a live audio webcast of the call via the investors section of the Company’s website www.summitplc.com. A replay of the webcast will be available shortly after the presentation finishes.
 
About Summit Therapeutics 
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficileinfection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
 
For more information, please contact:
 
Summit Therapeutics  
Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski / Michelle Avery (US office)		 Tel: +44 (0)1235 443 951
        +1 617 225 4455
   
Cairn Financial Advisers LLP  
(Nominated Adviser)
Liam Murray / Tony Rawlinson		 Tel: +44 (0)20 7148 7900
   
N+1 Singer  
(Broker)
Aubrey Powell / Jen Boorer 		 Tel: +44 (0)20 7496 3000
   
MacDougall Biomedical Communications  
(US media contact)
Chris Erdman / Karen Sharma		 Tel: +1 781 235 3060
This email address is being protected from spambots. You need JavaScript enabled to view it. 
This email address is being protected from spambots. You need JavaScript enabled to view it. 
 
   
Consilium Strategic Communications  
(Financial public relations, UK)
Mary-Jane Elliott / Sue Stuart / 
Jessica Hodgson / Lindsey Neville		 Tel: +44 (0)20 3709 5700
This email address is being protected from spambots. You need JavaScript enabled to view it.

-END-